CN Patent

CN112312893A — 奥德昔巴特的药物制剂

Assigned to Albireo AB · Expires 2021-02-02 · 5y expired

What this patent protects

本发明涉及药物制剂，例如，包含多个小颗粒的奥德昔巴特的儿科制剂。所述制剂可用于治疗肝病，例如胆汁酸依赖性肝病，特别是胆汁淤积性肝病(例如胆道闭锁、进行性家族性肝内胆汁淤积(PFIC)、阿拉杰里综合征(ALGS)和小儿胆汁淤积瘙痒症)。本发明还涉及制备所述药物制剂的方法。

USPTO Abstract

本发明涉及药物制剂，例如，包含多个小颗粒的奥德昔巴特的儿科制剂。所述制剂可用于治疗肝病，例如胆汁酸依赖性肝病，特别是胆汁淤积性肝病(例如胆道闭锁、进行性家族性肝内胆汁淤积(PFIC)、阿拉杰里综合征(ALGS)和小儿胆汁淤积瘙痒症)。本发明还涉及制备所述药物制剂的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN112312893A
Jurisdiction
CN
Classification
—
Expires
2021-02-02
Drug substance claim
No
Drug product claim
No
Assignee
Albireo AB
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.